Robotic Microtool Control in an Intelligent Automated In Vitro Fertilization and Intracytoplasmic Sperm Injection Platform
US-2024426856-A1 · Dec 26, 2024 · US
Marker for determination of sensitivity to anticancer agent
US9797884B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9797884-B2 |
| Application number | US-201214007145-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 24, 2012 |
| Priority date | Mar 24, 2011 |
| Publication date | Oct 24, 2017 |
| Grant date | Oct 24, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD + , or a substance involved in the metabolism of any of these substances.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for determining sensitivity of a subject having colorectal cancer to an anti-cancer agent, which is oxaliplatin or a salt thereof, the method comprising: a) administering oxaliplatin or a salt thereof to a subject having colorectal cancer; b) obtaining a specimen from the subject; and c) measuring a level of N-acetylglucosamine in the specimen. 2. The method of claim 1 , further comprising comparing the level of N-acetylglucosamine in the specimen to a standard, and administering oxaliplatin or a salt thereof to the subject having colorectal cancer when the level of N-acetylglucosamine in the specimen is the same or less compared to the standard.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
for cancer · CPC title
Metabolic pathways · CPC title
Platinum compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9797884B2 cover?
- A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine…
- Who is the assignee on this patent?
- Tanigawara Yusuke, Nishimuta Akito, Otani Yuki, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5091. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).